BACKGROUND: Diffuse large B-cell lymphoma is a clinically and molecularly heterogeneous disease. Gene expression profiling studies have shown that the tumor microenvironment affects survival and that the angiogenesis-related signature is prognostically unfavorable. The contribution of histopathological microvessel density to survival in diffuse large B-cell lymphomas treated with immunochemotherapy remains unknown. The purpose of this study is to assess the prognostic impact of histopathological microvessel density in two independent series of patients with diffuse large B-cell lymphoma treated with immunochemotherapy. DESIGN AND METHODS: One hundred and forty-seven patients from the Leukemia Lymphoma Molecular Profiling Project (training series) and 118 patients from the Catalan Lymphoma-Study group-GELCAB (validation cohort) were included in the study. Microvessels were immunostained with CD31 and quantified with a computerized image analysis system. The stromal scores previously defined in 110 Leukemia Lymphoma Molecular Profiling Project cases were used to analyze correlations with microvessel density data. RESULTS: Microvessel density significantly correlated with the stromal score (r=0.3209; P<0.001). Patients with high microvessel density showed significantly poorer overall survival than those with low microvessel density both in the training series (4-year OS 54% vs. 78%; P=0.004) and in the validation cohort (57% vs. 81%; P=0.006). In multivariate analysis, in both groups high microvessel density was a statistically significant unfavorable prognostic factor independent of international prognostic index [training series: international prognostic index (relative risk 2.7; P=0.003); microvessel density (relative risk 1.96; P=0.002); validation cohort: international prognostic index (relative risk 4.74; P<0.001); microvessel density (relative risk 2.4; P=0.016)]. CONCLUSIONS: These findings highlight the impact of angiogenesis in the outcome of patients with diffuse large B-cell lymphoma and the interest of evaluating antiangiogenic drugs in clinical trials.
BACKGROUND: Diffuse large B-cell lymphoma is a clinically and molecularly heterogeneous disease. Gene expression profiling studies have shown that the tumor microenvironment affects survival and that the angiogenesis-related signature is prognostically unfavorable. The contribution of histopathological microvessel density to survival in diffuse large B-cell lymphomas treated with immunochemotherapy remains unknown. The purpose of this study is to assess the prognostic impact of histopathological microvessel density in two independent series of patients with diffuse large B-cell lymphoma treated with immunochemotherapy. DESIGN AND METHODS: One hundred and forty-seven patients from the Leukemia Lymphoma Molecular Profiling Project (training series) and 118 patients from the Catalan Lymphoma-Study group-GELCAB (validation cohort) were included in the study. Microvessels were immunostained with CD31 and quantified with a computerized image analysis system. The stromal scores previously defined in 110 Leukemia Lymphoma Molecular Profiling Project cases were used to analyze correlations with microvessel density data. RESULTS: Microvessel density significantly correlated with the stromal score (r=0.3209; P<0.001). Patients with high microvessel density showed significantly poorer overall survival than those with low microvessel density both in the training series (4-year OS 54% vs. 78%; P=0.004) and in the validation cohort (57% vs. 81%; P=0.006). In multivariate analysis, in both groups high microvessel density was a statistically significant unfavorable prognostic factor independent of international prognostic index [training series: international prognostic index (relative risk 2.7; P=0.003); microvessel density (relative risk 1.96; P=0.002); validation cohort: international prognostic index (relative risk 4.74; P<0.001); microvessel density (relative risk 2.4; P=0.016)]. CONCLUSIONS: These findings highlight the impact of angiogenesis in the outcome of patients with diffuse large B-cell lymphoma and the interest of evaluating antiangiogenic drugs in clinical trials.
Authors: Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph M Connors; Thomas M Grogan; Rita Braziel; Richard I Fisher; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald Journal: Blood Date: 2005-07-26 Impact factor: 22.113
Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Friedrich Feuerhake; Jeffery L Kutok; Stefano Monti; Wen Chen; Ann S LaCasce; Giorgio Cattoretti; Paul Kurtin; Geraldine S Pinkus; Laurence de Leval; Nancy L Harris; Kerry J Savage; Donna Neuberg; Thomas M Habermann; Riccardo Dalla-Favera; Todd R Golub; Jon C Aster; Margaret A Shipp Journal: Blood Date: 2005-05-03 Impact factor: 22.113
Authors: Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt Journal: N Engl J Med Date: 2002-06-20 Impact factor: 91.245
Authors: Anamarija M Perry; Teresa M Cardesa-Salzmann; Paul N Meyer; Luis Colomo; Lynette M Smith; Kai Fu; Timothy C Greiner; Jan Delabie; Randy D Gascoyne; Lisa Rimsza; Elaine S Jaffe; German Ott; Andreas Rosenwald; Rita M Braziel; Raymond Tubbs; James R Cook; Louis M Staudt; Joseph M Connors; Laurie H Sehn; Julie M Vose; Armando López-Guillermo; Elias Campo; Wing C Chan; Dennis D Weisenburger Journal: Blood Date: 2012-06-26 Impact factor: 22.113
Authors: Pavla Veselá; Zbyněk Tonar; David Sálek; Samuel Vokurka; Marek Trněný; Roman Kodet; Mojmír Moulis; Petra Kašparová; Zdeňka Vernerová; Zuzana Velenská; Jan Stříteský; Michal Michal; Ludmila Boudová Journal: Virchows Arch Date: 2014-07-22 Impact factor: 4.064
Authors: Annette M Staiger; Michael Altenbuchinger; Marita Ziepert; Christian Kohler; Heike Horn; Michael Huttner; Katrin S Hüttl; Gunther Glehr; Wolfram Klapper; Monika Szczepanowski; Julia Richter; Harald Stein; Alfred C Feller; Peter Möller; Martin-Leo Hansmann; Viola Poeschel; Gerhard Held; Markus Loeffler; Norbert Schmitz; Lorenz Trümper; Tobias Pukrop; Andreas Rosenwald; German Ott; Rainer Spang Journal: Leukemia Date: 2019-09-17 Impact factor: 11.528
Authors: John F Seymour; Michael Pfreundschuh; Marek Trnĕný; Laurie H Sehn; John Catalano; Eva Csinady; Nicola Moore; Bertrand Coiffier Journal: Haematologica Date: 2014-06-03 Impact factor: 9.941